Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Kaewkangsadan, Viriya ^a   Verma, Chandan ^a   Eremin, Jennifer M ^b   Cowley, Gerard ^b   Ilyas, Mohammed ^c   Eremin, Oleg ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CAPECITABINE; CD4 ANTIGEN; CD8 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; IL17A PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SIZE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; CYTOKINE RELEASE; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; CELL DEATH; IMMUNOLOGY; LYMPHOCYTE COUNT; NEOADJUVANT THERAPY; PATHOPHYSIOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CHEMOTHERAPY, ADJUVANT; CYTOKINES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; TUMOR MICROENVIRONMENT;

EID: 84991717317     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/4757405     Document Type: Article

References (106)

1. M. Aloysius, L. Walker, and O. Eremin, "Cancer and the immune response, " in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 4, pp. 237-302, OUP, Oxford, UK, 2011.
2. W. H. Fridman, F. Pagès, C. Sautès-Fridman, and J. Galon, "The immune contexture in human tumours: impact on clinical outcome, " Nature Reviews Cancer, vol. 12, no. 4, pp. 298-306, 2012.
3. J. Galon, H. K. Angell, D. Bedognetti, and F. M. Marincola, "The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, " Immunity, vol. 39, no. 1, pp. 11-26, 2013.
4. H. Angell and J. Galon, "From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer, " Current Opinion in Immunology, vol. 25, no. 2, pp. 261-267, 2013.
5. M. W. L. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, "Classifying cancers based on T-cell infiltration and PD-L1, " Cancer Research, vol. 75, no. 11, pp. 2139-2145, 2015.
6. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, " New England Journal of Medicine, vol. 348, no. 3, pp. 203-213, 2003.
7. F. Pagès, A. Berger, M. Camus et al., "Effector memory T cells, early metastasis, and survival in colorectal cancer, " The New England Journal of Medicine, vol. 353, no. 25, pp. 2654-2666, 2005.
8. G. Schiavoni, L. Gabriele, and F. Mattei, "The tumor microenvironment: A pitch for multiple players, " Frontiers in Oncology, vol. 3, article 90, 2013.
9. C. Denkert, S. Loibl, A. Noske et al., "Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, " Journal of Clinical Oncology, vol. 28, no. 1, pp. 105-113, 2010.
10. F. Andre, N. Berrada, and C. Desmedt, "Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients, " Current Opinion in Oncology, vol. 22, no. 6, pp. 547-551, 2010.
11. R. Yamaguchi, M. Tanaka, A. Yano et al., "Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer, " Human Pathology, vol. 43, no. 10, pp. 1688-1694, 2012.
12. S. A. Oldford, J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover, "Tumor cell expression of HLA-DMassociates with a Th1 profile and predicts improved survival in breast carcinoma patients, " International Immunology, vol. 18, no. 11, pp. 1591-1602, 2006.
13. S. Ladoire, L. Arnould, L. Apetoh et al., "Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells, " Clinical Cancer Research, vol. 14, no. 8, pp. 2413-2420, 2008.
14. A. Balsari, A. Merlo, P. Casalini et al., "FOXP3 expression and overall survival in breast cancer, " Journal of Clinical Oncology, vol. 27, no. 11, pp. 1746-1752, 2009.
15. S. M. A. Mahmoud, E. C. Paish, D. G. Powe et al., "Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, " Journal of Clinical Oncology, vol. 29, no. 15, pp. 1949-1955, 2011.
16. S. M. A. Mahmoud, E. C. Paish, D. G. Powe et al., "An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer, " Breast Cancer Research and Treatment, vol. 127, no. 1, pp. 99-108, 2011.
17. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, "Immunological aspects of cancer chemotherapy, " Nature Reviews Immunology, vol. 8, no. 1, pp. 59-73, 2008.
18. M. Aloysius, C. Verma, and O. Eremin, "Therapy and host defences, " in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 7, pp. 379-402, OUP, Oxford, UK, 2011.
19. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, "Immunogenic cell death in cancer therapy, " Annual Review of Immunology, vol. 31, pp. 51-72, 2013.
20. C. Verma, V. Kaewkangsadan, J. M. Eremin et al., "Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery, " Journal of Translational Medicine, vol. 13, article 180, 2015.
21. C. Verma, J. M. Eremin, A. Robins et al., "Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response toNAC, " Journal of TranslationalMedicine, vol. 11, no. 1, article 16, 2013.
22. A. M. Malyguine, S. L. Strobl, and M. R. Shurin, "Immunological monitoring of the tumor immunoenvironment for clinical trials, " Cancer Immunology, Immunotherapy, vol. 61, no. 2, pp. 239-247, 2012.
23. G. von Minckwitz, M. Untch, J.-U. Blohmer et al., "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, " Journal of Clinical Oncology, vol. 30, no. 15, pp. 1796-1804, 2012.
24. J. Eremin, G. Cowley, L. G. Walker, E. Murray, M. Stovickova, and O. Eremin, "Women with large (? 3cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): Addition of capecitabine improves 4-year diseasefree survival, " SpringerPlus, vol. 4, article 9, 2015.
25. K. N. Ogston, I. D. Miller, S. Payne et al., "A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival, " Breast, vol. 12, no. 5, pp. 320-327, 2003.
26. L. G. Walker, J. M. Eremin, M. M. Aloysius et al., "Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer, " BMC Cancer, vol. 11, article 179, 2011.
27. N. Oda, K. Shimazu, Y. Naoi et al., "Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients, " Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 107-116, 2012.
28. L. Demir, S. Yigit, H. Ellidokuz et al., "Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs, " Clinical & ExperimentalMetastasis, vol. 30, no. 8, pp. 1047-1062, 2013.
29. M. V. Dieci, C. Criscitiello, A. Goubar et al., "Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study, " Annals of Oncology, vol. 25, no. 3, pp. 611-618, 2014.
30. R. Salgado, C. Denkert, S. Demaria et al., "The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014, " Annals of Oncology, vol. 26, no. 2, Article IDmdu450, pp. 259-271, 2015.
31. J. Galon, A. Costes, F. Sanchez-Cabo et al., "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, " Science, vol. 313, no. 5795, pp. 1960-1964, 2006.
32. N. Leffers, M. J. M. Gooden, R. A. De Jong et al., "Prognostic significance of tumor-infiltrating T-lymphocytes in primary and Metastatic lesions of advanced stage ovarian cancer, " Cancer Immunology, Immunotherapy, vol. 58, no. 3, pp. 449-459, 2009.
33. S. Demaria, M. D. Volm, R. L. Shapiro et al., "Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, " Clinical Cancer Research, vol. 7, no. 10, pp. 3025-3030, 2001.
34. M. Ono, H. Tsuda, C. Shimizu et al., "Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, " Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 793-805, 2012.
35. N. R. West, K. Milne, P. T. Truong, N. Macpherson, B. H. Nelson, and P. H. Watson, "Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer, " Breast Cancer Research, vol. 13, no. 6, article R126, 2011.
36. S. Loi, N. Sirtaine, F. Piette et al., "Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, " Journal of Clinical Oncology, vol. 31, no. 7, pp. 860-867, 2013.
37. R. Droeser, I. Zlobec, E. Kilic et al., "Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers, " BMC Cancer, vol. 12, article 134, 2012.
38. S. D. Heys, K. N. Stewart, E. J. McKenzie et al., "Characterisation of tumour-infiltrating macrophages: Impact on response and survival in patients receiving primary chemotherapy for breast cancer, " Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 539-548, 2012.
39. R. Matkowski, I. Gisterek, A. Halon et al., "The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer, " Anticancer Research, vol. 29, no. 7, pp. 2445-2451, 2009.
40. S. Ladoire, G. Mignot, S. Dabakuyo et al., "In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, "The Journal of Pathology, vol. 224, no. 3, pp. 389-400, 2011.
41. A. C. Degnim, R. D. Brahmbhatt, D. C. Radisky et al., "Immune cell quantitation in normal breast tissue lobules with and without lobulitis, " Breast Cancer Research and Treatment, vol. 144, no. 3, pp. 539-549, 2014.
42. H. J. Lee, J.-Y. Seo, J.-H. Ahn, S.-H. Ahn, and G. Gong, "Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients, " Journal of Breast Cancer, vol. 16, no. 1, pp. 32-39, 2013.
43. A. N. Seo, H. J. Lee, E. J. Kim et al., "Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer, " British Journal of Cancer, vol. 109, no. 10, pp. 2705-2713, 2013.
44. E. García-Martínez, G. L. Gil, A. C. Benito et al., "Tumorinfiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer, " Breast Cancer Research, vol. 16, no. 6, article 488, 2014.
45. H. Sewell, "Basic immunology, " in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 1, pp. 1-160, OUP, Oxford, UK, 2011.
46. C. T. Mayer, S. Floess, A. M. Baru, K. Lahl, J. Huehn, and T. Sparwasser, "CD8+Foxp3+ T cells share developmental and phenotypic features with classical CD4+Foxp3+ regulatory T cells but lack potent suppressive activity, " European Journal of Immunology, vol. 41, no. 3, pp. 716-725, 2011.
47. F. Liu, Y. Li, M. Ren et al., "Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients, " Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 459-467, 2012.
48. G. J. Bates, S. B. Fox, C. Han et al., "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, " Journal of Clinical Oncology, vol. 24, no. 34, pp. 5373-5380, 2006.
49. A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein, "Increase of regulatory T cells in the peripheral blood of cancer patients, " Clinical Cancer Research, vol. 9, no. 2, pp. 606-612, 2003.
50. S. A. Perez, M. V. Karamouzis, D. V. Skarlos et al., "CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients, " Clinical Cancer Research, vol. 13, no. 9, pp. 2714-2721, 2007.
51. D. J. Campbell and M. A. Koch, "Phenotypical and functional specialization of FOXP3+ regulatory T cells, " Nature Reviews Immunology, vol. 11, no. 2, pp. 119-130, 2011.
52. E. M. Shevach, "Mechanisms of Foxp3+ T regulatory cellmediated suppression, " Immunity, vol. 30, no. 5, pp. 636-645, 2009.
53. H. Nishikawa and S. Sakaguchi, "Regulatory T cells in tumor immunity, " International Journal of Cancer, vol. 127, no. 4, pp. 759-767, 2010.
54. U. K. Liyanage, T. T. Moore, H.-G. Joo et al., "Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, " Journal of Immunology, vol. 169, no. 5, pp. 2756-2761, 2002.
55. R. P. Petersen, M. J. Campa, J. Sperlazza et al., "Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients, " Cancer, vol. 107, no. 12, pp. 2866-2872, 2006.
56. Q. Gao, S.-J. Qiu, J. Fan et al., "Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection, " Journal of Clinical Oncology, vol. 25, no. 18, pp. 2586-2593, 2007.
57. S. Ladoire, F. Martin, and F. Ghiringhelli, "Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer, " Cancer Immunology, Immunotherapy, vol. 60, no. 7, pp. 909-918, 2011.
58. M. Gobert, I. Treilleux, N. Bendriss-Vermare et al., "Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, " Cancer Research, vol. 69, no. 5, pp. 2000-2009, 2009.
59. N. R. West, S. E. Kost, S. D. Martin et al., "Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptornegative breast cancer, " British Journal of Cancer, vol. 108, no. 1, pp. 155-162, 2013.
60. S. Ladoire, L. Arnould, G. Mignot et al., "Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy, " Breast Cancer Research and Treatment, vol. 125, no. 1, pp. 65-72, 2011.
61. W. A. Teft, M. G. Kirchhof, and J. Madrenas, "A molecular perspective of CTLA-4 function, " Annual Review of Immunology, vol. 24, pp. 65-97, 2006.
62. W. A. Teft and J. Madrenas, "Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4, " Journal of Immunology, vol. 179, no. 6, pp. 3631-3637, 2007.
63. M. K. Levings, R. Sangregorio, and M.-G. Roncarolo, "Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function, "The Journal of ExperimentalMedicine, vol. 193, no. 11, pp. 1295-1302, 2001.
64. D. M. Sansom and L. S. K. Walker, "The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory Tcell biology, " Immunological Reviews, vol. 212, pp. 131-148, 2006.
65. T. L. Walunas, C. Y. Bakker, and J. A. Bluestone, "CTLA-4 ligation blocks CD28-dependent T cell activation, " The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2541-2550, 1996.
66. H. Mao, L. Zhang, Y. Yang et al., "New insights of CTLA-4 into its biological function in breast cancer, " Current Cancer Drug Targets, vol. 10, no. 7, pp. 728-736, 2010.
67. L. de la Cruz-Merino, A. Barco-Sánchez, F. Henao Carrasco et al., "New insights into the role of the immune microenvironment in breast carcinoma, " Clinical & Developmental Immunology, vol. 2013, Article ID 785317, 11 pages, 2013.
68. T. Shinohara, M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo, "Structure and chromosomal localization of the human PD-1 gene (PDCD1), " Genomics, vol. 23, no. 3, pp. 704-706, 1994.
69. J. Y. Park, M. J. Jang, Y. H. Chung et al., "Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB, " International Immunopharmacology, vol. 9, no. 13-14, pp. 1530-1539, 2009.
70. S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, " CurrentOpinion in Immunology, vol. 24, no. 2, pp. 207-212, 2012.
71. S. Ostrand-Rosenberg, L. A. Horn, and S. T. Haile, "The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity, " Journal of Immunology, vol. 193, no. 8, pp. 3835-3841, 2014.
72. C. Criscitiello and G. Curigliano, "Immunotherapeutics for breast cancer, " Current Opinion in Oncology, vol. 25, no. 6, pp. 602-608, 2013.
73. H. Dong, S. E. Strome, D. R. Salomao et al., "Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, " Nature Medicine, vol. 8, no. 8, pp. 793-800, 2002.
74. Y. Cao, L. Zhang, P. Ritprajak et al., "Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis, " Cancer Research, vol. 71, no. 14, pp. 4737-4741, 2011.
75. A. Flemming, "Cancer: PD1 makes waves in anticancer immunotherapy, " Nature Reviews Drug Discovery, vol. 11, no. 8, article 601, 2012.
76. S. Sun, X. Fei, Y. Mao et al., "PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients, " Cancer Immunology, Immunotherapy, vol. 63, no. 4, pp. 395-406, 2014.
77. S. Chouaib, C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay, "The host-tumor immune conflict: fromimmunosuppression to resistance and destruction, " Immunology Today, vol. 18, no. 10, pp. 493-497, 1997.
78. T. E. Reichert, S. Watkins, J. Stanson, J. T. Johnson, and T. L. Whiteside, "Endogenous IL-2 in cancer cells: A marker of cellular proliferation, " Journal of Histochemistry and Cytochemistry, vol. 46, no. 5, pp. 603-611, 1998.
79. S. Schweyer, A. Soruri, J. Peters, A. Wagner, H. J. Radzun, and A. Fayyazi, "Malignant germ cell tumours of the testis express interferon-, but are resistant to endogenous interferon-, " British Journal of Cancer, vol. 89, no. 5, pp. 915-921, 2003.
80. L. Llanes-Fernández, R. I. Álvarez-Goyanes, M. D. C. Arango-Prado et al., "Relationship between IL-10 and tumormarkers in breast cancer patients, " Breast, vol. 15, no. 4, pp. 482-489, 2006.
81. L. Yang, Y. Qi, J. Hu, L. Tang, S. Zhao, and B. Shan, "Expression of Th17 cells in breast cancer tissue and its association with clinical parameters, " Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 153-159, 2012.
82. Q. Liu, M. R. Russell, K. Shahriari et al., "Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features, " Cancer Research, vol. 73, no. 11, pp. 3297-3305, 2013.
83. F. Nutter, I. Holen, H. K. Brown et al., "Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line, " Endocrine-Related Cancer, vol. 21, no. 2, pp. 327-341, 2014.
84. R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón, "The polarization of immune cells in the tumour environment by TGF, " Nature Reviews Immunology, vol. 10, no. 8, pp. 554-567, 2010.
85. P. Maerten, C. Shen, D. M. A. Bullens et al., "Effects of interleukin 4 on CD25+CD4+ regulatory T cell function, " Journal of Autoimmunity, vol. 25, no. 2, pp. 112-120, 2005.
86. B. B. L. Pillemer, Z. Qi, B. Melgert, T. B. Oriss, P. Ray, and A. Ray, "STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells, " Journal of Immunology, vol. 183, no. 1, pp. 155-163, 2009.
87. T. Kato, H. Furumoto, T. Ogura et al., "Expression of IL-17 mRNA in ovarian cancer, " Biochemical and Biophysical Research Communications, vol. 282, no. 3, pp. 735-738, 2001.
88. M. Numasaki, J.-I. Fukushi, M. Ono et al., "Interleukin-17 promotes angiogenesis and tumor growth, " Blood, vol. 101, no. 7, pp. 2620-2627, 2003.
89. T. Yamazaki, X. O. Yang, Y. Chung et al., "CCR6 regulates the migration of inflammatory and regulatory T cells, " Journal of Immunology, vol. 181, no. 12, pp. 8391-8401, 2008.
90. F. Benchetrit, A. Ciree, V. Vives et al., "Interleukin-17 inhibits tumor cell growth bymeans of a T-cell-dependent mechanism, " Blood, vol. 99, no. 6, pp. 2114-2121, 2002.
91. C. M. Wilke, I. Kryczek, S. Wei et al., "Th17 cells in cancer: help or hindrance" Carcinogenesis, vol. 32, no. 5, pp. 643-649, 2011.
92. B. Bierie and H. L. Moses, "Transforming growth factor beta (TGF-β) and inflammation in cancer, " Cytokine & Growth Factor Reviews, vol. 21, no. 1, pp. 49-59, 2010.
93. G. Wei, L. Wei, J. Zhu et al., "Global mapping of H3K4me3 and H3k27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells, " Immunity, vol. 30, no. 1, pp. 155-167, 2009.
94. L. Xu, A. Kitani, I. Fuss, and W. Strober, "Cutting edge: regulatory T cells induce CD4+CD25?Foxp3? T cells or are selfinduced to becomeTh17 cells in the absence of exogenous TGF-β, " The Journal of Immunology, vol. 178, no. 11, pp. 6725-6729, 2007.
95. N. Tsavaris, C. Kosmas, M. Vadiaka, P. Kanelopoulos, and D. Boulamatsis, "Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes, " British Journal of Cancer, vol. 87, no. 1, pp. 21-27, 2002.
96. C. M. Barbon, M. Yang, G. D. Wands et al., "Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization, " Cellular Immunology, vol. 262, no. 2, pp. 150-161, 2010.
97. D. T. Le and E. M. Jaffee, "Regulatory T-cellmodulation using cyclophosphamide in vaccine approaches: A current perspective, " Cancer Research, vol. 72, no. 14, pp. 3439-3444, 2012.
98. N. Casares, M. O. Pequignot, A. Tesniere et al., "Caspasedependent immunogenicity of doxorubicin-induced tumor cell death, " The Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691-1701, 2005.
99. A. D. Garg, D. V. Krysko, T. Verfaillie et al., "A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death, " The EMBO Journal, vol. 31, no. 5, pp. 1062-1079, 2012.
100. L. Menger, E. Vacchelli, S. Adjemian et al., "Cardiac glycosides exert anticancer effects by inducing immunogenic cell death, " Science Translational Medicine, vol. 4, no. 143, Article ID 143ra99, 2012.
101. S. R. Mattarollo, S. Loi, H. Duret, Y. Ma, L. Zitvogel, and M. J. Smyth, "Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors, " Cancer Research, vol. 71, no. 14, pp. 4809-4820, 2011.
102. F. Ghiringhelli, C. Menard, P. E. Puig et al., "Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, " Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641-648, 2007.
103. A. W. Tong, B. Seamour, J. M. Lawson et al., "Cellular immune profile of patients with advanced cancer before and after taxane treatment, " American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 23, no. 5, pp. 463-472, 2000.
104. G. M. Weir, R. S. Liwski, and M. Mansour, "Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines, " Cancers, vol. 3, no. 3, pp. 3114-3142, 2011.
105. J. Vincent, G. Mignot, F. Chalmin et al., "5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, " Cancer Research, vol. 70, no. 8, pp. 3052-3061, 2010.
106. E. J. Wherry and M. Kurachi, "Molecular and cellular insights into T cell exhaustion, " Nature Reviews Immunology, vol. 15, no. 8, pp. 486-499, 2015.